Northern Trust Corp Boosts Stake in Teladoc Health, Inc. (NYSE:TDOC)

Northern Trust Corp raised its position in Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 10.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,679,382 shares of the health services provider's stock after purchasing an additional 161,875 shares during the period. Northern Trust Corp owned 0.98% of Teladoc Health worth $15,266,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Teladoc Health by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 18,463,155 shares of the health services provider's stock valued at $167,830,000 after acquiring an additional 1,029,829 shares during the period. Renaissance Technologies LLC boosted its holdings in Teladoc Health by 15.5% during the 4th quarter. Renaissance Technologies LLC now owns 5,674,542 shares of the health services provider's stock valued at $51,582,000 after acquiring an additional 763,265 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Teladoc Health by 20,936.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 426,206 shares of the health services provider's stock worth $3,874,000 after acquiring an additional 424,180 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Teladoc Health by 18.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,443,713 shares of the health services provider's stock valued at $22,213,000 after buying an additional 384,528 shares in the last quarter. Finally, Wealthfront Advisers LLC purchased a new position in shares of Teladoc Health in the fourth quarter worth $3,364,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teladoc Health news, insider Adam C. Vandervoort sold 11,011 shares of the business's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the transaction, the insider now owns 64,308 shares of the company's stock, valued at approximately $541,473.36. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.58% of the stock is currently owned by corporate insiders.

Teladoc Health Stock Down 0.9%

NYSE TDOC traded down $0.07 during trading on Tuesday, hitting $7.25. The stock had a trading volume of 190,261 shares, compared to its average volume of 6,218,870. The company's 50-day moving average price is $7.55 and its two-hundred day moving average price is $9.35. The company has a market capitalization of $1.27 billion, a PE ratio of -1.26 and a beta of 1.82. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. Teladoc Health, Inc. has a 12 month low of $6.35 and a 12 month high of $15.21.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.07). The firm had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. As a group, sell-side analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

TDOC has been the topic of several analyst reports. Bank of America lowered their target price on Teladoc Health from $9.50 to $8.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Royal Bank of Canada boosted their price objective on Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a research report on Friday, January 24th. The Goldman Sachs Group reduced their target price on Teladoc Health from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Evercore ISI reduced their target price on Teladoc Health from $8.00 to $7.00 and set an "in-line" rating on the stock in a report on Thursday, May 1st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Teladoc Health in a research note on Thursday, May 1st. Twelve analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $9.71.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.